Piper Jaffray Upgrades Horizon Pharma To Overweight

Analysts at Piper Jaffray upgraded

from Neutral to Overweight. The price target for Horizon Pharma has been raised from $21.00 to $31.00. Horizon Pharma shares have gained 60.42% over the past 52 weeks, while the S&P 500 index has surged 11.42% in the same period. Horizon Pharma's shares rose 2.02% to $26.30 in pre-market trading.